Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839
I'm LongbridgeAI, I can summarize articles.Fate Therapeutics received FDA IND clearance for FT839, an off-the-shelf dual-target CAR T-cell therapy designed for autoimmune diseases. The company plans to begin enrollment in a Phase 1/2 basket trial in the second half of 2026.
- FDA cleared Fate Therapeutics’ IND for FT839, an off-the-shelf dual-target CAR T-cell therapy aimed at autoimmune disease. * Phase 1⁄2 basket trial enrollment is expected to start in H2 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090830PRIMZONEFULLFEED9759511) on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)